Caveolin-1 temporal modulation enhances trastuzumab and trastuzumab-drug conjugate efficacy in heterogeneous gastric cancer
P. M. R. Pereira, K. Mandleywala, S. Monette, M. Lumish, K. M. Tully, M. Cornejo, A. Mauguen, A. Ragupathi, M. Mattar, Y. Y. Janjigian, J. S. Lewis
This paper identifies CAV1 as a biomarker for trastuzumab efficacy in HER2-positive gastric cancer and shows that statin use enhances antibody therapy response.
bioRxiv · Jul 13, 2021 · PreprintCancer Biology